Japan approves Sanofi’s Sarclisa combo for MM treatment

Sanofi has received approval from Japan's Ministry of Health, Labour and Welfare for its SC formulation of Sarclisa in combination with standard therapies to treat multiple myeloma. The approved indications include combining Sarclisa SC with Pd, or with carfilzomib for relapsed or refractory multiple myeloma. Pivotal data from the IRAKLIA Phase III study showed a 71.1% ORR for Sarclisa SC-Pd via OBI. Credit: luchschenF / Shutterstock.com. Sanofi has received approval from Japan’s Ministry of Health, Labour and Welfare for its subcutaneous (SC) formulation of Sarclisa (isatuximab) in combination with standard therapies to treat multiple myeloma (MM). The approval follows a…

Source: Pharmaceutical Technology